title: Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.
abstract: The aim of this study was to investigate the following in a large population of French patients with chronic hepatitis C: the geographical distribution of hepatitis C virus (HCV) genotypes; the relationship between HCV genotypes and epidemiological characteristics; severity of the disease; and response to interferon (IFN) therapy. Data from 14 tertiary referral centres, corresponding to 1872 patients with chronic hepatitis C, were prospectively collected from 1989 to 1997. HCV genotyping was performed using the line probe assay (LiPA). HCV genotypes 1b, 3, 1a, 2, 4 and a mixed infection were found in 41%, 22%, 16%, 11%, 4% and 4% of our population, respectively. HCV genotype distribution was homogeneous, except for genotype 2 that was found more frequently in the southwest than in the other regions (21% vs 9.2%) (P=0.001). HCV distribution was associated with gender, age, and source and duration of infection. In multivariate analysis, these correlations were related to the source of infection, which was the only independent factor significantly associated with genotype (P=0.001). Genotype 1b was significantly more common in patients with cirrhosis, but in multivariate analysis cirrhosis was independently related to older age at exposure and longer duration of infection (P=0.001). A sustained response to IFN therapy was observed in 11% of patients infected with genotypes 1a or 1b vs 32% of those infected with genotypes 2 or 3 (P=0.001). This study shows that HCV genotype is mainly related to the source infection, but not to the intrinsic pathogenicity of HCV, and is a strong predictor of sustained response to therapy.
authors.affiliation: Unité de Recherche INSERM U481 and Centre de Recherche Claude Bernard sur les Hépatites Virales, Hôpital Beaujon, Clichy.
authors.forename: M
authors.initials: M
authors.lastname: Martinot-Peignoux
authors.forename: F
authors.initials: F
authors.lastname: Roudot-Thoraval
authors.forename: I
authors.initials: I
authors.lastname: Mendel
authors.forename: J
authors.initials: J
authors.lastname: Coste
authors.forename: J
authors.initials: J
authors.lastname: Izopet
authors.forename: G
authors.initials: G
authors.lastname: Duverlie
authors.forename: C
authors.initials: C
authors.lastname: Payan
authors.forename: J M
authors.initials: JM
authors.lastname: Pawlotsky
authors.forename: C
authors.initials: C
authors.lastname: Defer
authors.forename: M
authors.initials: M
authors.lastname: Bogard
authors.forename: V
authors.initials: V
authors.lastname: Gerolami
authors.forename: P
authors.initials: P
authors.lastname: Halfon
authors.forename: Y
authors.initials: Y
authors.lastname: Buisson
authors.forename: B
authors.initials: B
authors.lastname: Fouqueray
authors.forename: P
authors.initials: P
authors.lastname: Loiseau
authors.forename: J
authors.initials: J
authors.lastname: Lamoril
authors.forename: J J
authors.initials: JJ
authors.lastname: Lefrere
authors.forename: P
authors.initials: P
authors.lastname: Marcellin
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005602:France / Q000453:epidemiology; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics* / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral